Exploring Nanotechnology as a Strategy to Circumvent Antimicrobial Resistance in Bone and Joint Infections

被引:6
作者
Skosana, Phumzile P. [1 ]
Mudenda, Steward [2 ]
Demana, Patrick H. [3 ]
Witika, Bwalya A. [3 ]
机构
[1] Sefako Makgatho Hlth Sci Univ, Sch Pharm, Dept Clin Pharm, ZA-0208 Pretoria, South Africa
[2] Univ Zambia, Sch Hlth Sci, Dept Pharm, Lusaka 10101, Zambia
[3] Sefako Makgatho Hlth Sci Univ, Sch Pharm, Dept Pharmaceut Sci, ZA-0208 Pretoria, South Africa
关键词
STAPHYLOCOCCUS-AUREUS; IN-VITRO; LOCAL-DELIVERY; NANOPARTICLES; OSTEOMYELITIS; ANTIBIOTICS; VANCOMYCIN; RELEASE; STEWARDSHIP; BACTERIA;
D O I
10.1021/acsomega.3c01225
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Bone and joint infections (BJIs) are difficult to treat, necessitating antimicrobial therapy at high doses for an extended period of time, in some cases different from our local guidelines. As a consequence of the rise in antimicrobial-resistant organisms, drugs that were previously reserved for last-line defense are now being used as first line treatment, and the pill burden and adverse effects on patients are leading to nonadherence, encouraging antimicrobial resistance (AMR) to these last-resort medicines. Nanodrug delivery is the field of pharmaceutical sciences and drug delivery which combines nanotechnology with chemotherapy and/or diagnostics to improve treatment and diagnostic outcomes by targeting specific cells or tissues affected. Delivery systems based on lipids, polymers, metals, and sugars have been used in an attempt to provide a way around AMR. This technology has the potential to improve drug delivery by targeting the site of infection and using the appropriate amount of antibiotics to treat BJIs caused by highly resistant organisms. This Review aims to provide an in-depth examination of various nanodrug delivery systems used to target the causative agents in BJI.
引用
收藏
页码:15865 / 15882
页数:18
相关论文
共 144 条
[1]   Going beyond the Control of Quorum-Sensing to Combat Biofilm Infections [J].
Abraham, Wolf-Rainer .
ANTIBIOTICS-BASEL, 2016, 5 (01)
[2]  
Agyare C., 2018, Intechopen, DOI DOI 10.5772/INTECHOPEN.79371
[3]   PMMA bone cement containing long releasing silica-based chlorhexidine nanocarriers [J].
Al Thaher, Yazan ;
Alotaibi, Hadil Faris ;
Yang, Lirong ;
Prokopovich, Polina .
PLOS ONE, 2021, 16 (09)
[4]   The impact of antimicrobial stewardship program implementation at four tertiary private hospitals: results of a five-years pre-post analysis [J].
Al-Omari, Awad ;
Al Mutair, Abbas ;
Alhumaid, Saad ;
Salih, Samer ;
Alanazi, Ahmed ;
Albarsan, Hesham ;
Abourayan, Maha ;
Al Subaie, Maha .
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 2020, 9 (01)
[5]   Enzyme responsive copolymer micelles enhance the anti-biofilm efficacy of the antiseptic chlorhexidine [J].
Albayaty, Yassamin N. ;
Thomas, Nicky ;
Jambhrunkar, Manasi ;
Al-Hawwas, Mohammed ;
Kral, Anita ;
Thorn, Chelsea R. ;
Prestidge, Clive A. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2019, 566 :329-341
[6]   Intracellular Staphylococcus aureus in bone and joint infections: A mechanism of disease recurrence, inflammation, and bone and cartilage destruction [J].
Alder, Kareme D. ;
Lee, Inkyu ;
Munger, Alana M. ;
Kwon, Hyuk-Kwon ;
Morris, Montana T. ;
Cahill, Sean V. ;
Back, JungHo ;
Yu, Kristin E. ;
Lee, Francis Y. .
BONE, 2020, 141
[7]   Development of novel ultrashort antimicrobial peptide nanoparticles with potent antimicrobial and antibiofilm activities against multidrug-resistant bacteria [J].
Almaaytah, Ammar ;
Mohammed, Gubran Khalil ;
Abualhaijaa, Ahmad ;
Al-Balas, Qosay .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 :3159-3170
[8]  
Alt V, 2004, ORTHOPADE, V33, P885, DOI 10.1007/s00132-004-0690-8
[9]   A brief history of the antibiotic era: lessons learned and challenges for the future [J].
Aminov, Rustam I. .
FRONTIERS IN MICROBIOLOGY, 2010, 1
[10]  
[Anonymous], 2020, Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline